Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.49 |
| ▸ | EGFR | P00533 | 7/20 | 0.42 |
| ▸ | ITK | Q08881 | 6/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15814145 | 0.85 | SYK (0.47) | SYKEGFRITKCCNT1CCNE1 | |
| SCHEMBL12518613 | 0.81 | SYK (0.71) | SYKEGFRITKCCNT1CCNE1 | |
| SCHEMBL18704244 | 0.80 | ITK (0.57) | SYKEGFRITKBTK | |
| SCHEMBL18712208 | 0.79 | EGFR (0.64) | SYKEGFRITKBTK | |
| SCHEMBL15828882 | 0.76 | EGFR (0.60) | SYKEGFRITKBTK | |
| SCHEMBL15828831 | 0.76 | SYK (0.37) | SYKEGFRITKBTK | |
| SCHEMBL691972 | 0.75 | NPC1 (0.48) | EGFR | |
| SCHEMBL12519774 | 0.74 | MAPK1 (0.54) | SYKEGFRITKAURKA | |
| SCHEMBL1036047 | 0.74 | EGFR (0.53) | SYKEGFRITKCCNT1CCNE1 | |
| SCHEMBL653263 | 0.73 | SYK (0.53) | SYKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | disclosed |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | disclosed |
| US-9549927-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549927-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150374690-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2015-12-31 | — | — | US | disclosed |
| US-20150374690-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2015-12-31 | — | — | US | disclosed |
| US-9126950-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126950-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2014100748-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374690-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885EGFR 1981/4885ITK 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.